Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Safety and Efficacy of Decitabine + Ipilimumab in Relapsed/Refractory MDS/AML in Posttransplant or Transplant-Naïve Settings

2020 Year in Review - AML - Leukemia

CTEP 10026, a multicenter, investigator-initiated phase 1 study, assessed the safety and clinical activity of the hypomethylating agent (HMA) decitabine (DAC) plus the checkpoint inhibitor ipilimumab (IPI) in patients with relapsed/refractory (R/R) myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML), with prior allogeneic hematopoietic stem-cell transplantation (allo-HSCT; arm A) and without prior allo-HSCT (arm B).

Patients were aged ≥18 years with R/R MDS (≥5% blasts), R/R AML, or untreated secondary AML. Prior HMA was initially permitted; however, the protocol was amended to exclude those with disease progression on HMA therapy within 12 weeks of study entry. Patients in arm A (post–allo-HSCT) were required to be >3 months post–donor-cell infusion, without prior acute graft-versus-host disease (GVHD) grade ≥3, be >2 weeks off immunosuppressive therapy, and have donor T-cell chimerism ≥20%. Patients received treatment in 28-day cycles with a lead-in single-agent DAC (cycle 0) followed by combination DAC + IPI for up to 1 year. DAC infusion was given at 20 mg/m2 on days 1 to 5, and IPI infusion was given at 3 mg/kg (dose level [DL]0), 5 mg/kg (DL1) or 10 mg/kg (DL2) on day 1 of cycles 1 to 4, 5, 7, 9 and 11. Dose-limiting toxicity was defined as grade ≥3 nonhematologic adverse event (AE), acute GVHD, and steroid-refractory, immune-related AE within 8 weeks of the initial IPI dose.

At the time of data cutoff, 37 of 47 (79%) patients received ≥1 doses of DAC + IPI. The median age for arm A was 67 years (range, 29-79) versus 75 years (range, 34-85) for arm B. Of the 37 patients, 36 had AML and 11 had MDS. The median number of prior regimens was 3 (range, 0-5) for arm A and 1 (range, 0-3) for arm B. In arms A and B, 17 and 14 patients had received prior HMA therapy, respectively. Next-generation sequencing revealed mutations most commonly in ASXL1 (n = 8); RUNX1 (n = 6), STAG2 and NRAS (n = 5 each); DNMT3A and TP53 (n = 4 each).

In arm A, 25 patients received DAC + IPI (7 at DL0, 3 at DL1, and 6 at DL2). The most common grade 3/4 nonhematologic AEs were aspartate aminotransferase elevation (n = 3), gamma-glutamyl transpeptidase elevation (n = 1), and respiratory failure (n = 1). There were 2 grade 5 nonhematologic AEs, stroke (n = 1) and sepsis (n = 1). Eight patients experienced immune-related AEs. Most immune-related AEs were reversible with steroids. Four patients achieved responses (3 with complete response [CR] and 1 with marrow CR). Two of the responders had immune-related AEs. The median time to response was 1.7 months.

In arm B, 22 patients received DAC + IPI. The most common nonhematologic grade 3/4 AEs were fatigue, lung infection, and dyspnea (n = 4 each); hyperglycemia, muscle weakness, and hypertension (n = 3 each); acute kidney injury, hyponatremia, hypoxia, and creatinine increase (n = 2 each); as well as respiratory failure (n = 1). Six patients experienced grade ≥2 immune-related AEs. Objective responses were detected in 9 patients (4 CR, 2 CR with incomplete hematologic recovery [CRi], and 3 marrow CR). Two responders had immune-related AEs. The median time to response was 3.9 months. In conclusion, patients with R/R or secondary MDS/AML treated with DAC + IPI exhibited encouraging clinical activity, with AE profiles as expected. Consistent with IPI 10 mg/kg for melanoma, the rate of immune-related toxicity was common. A high degree of clinical activity was observed in patients who did not receive allo-HSCT, indicating that an alloreactive environment may not be required for patients to benefit from blockade of cytotoxic T-lymphocyte-associated protein-4.

Reference

Garcia JS, Flamand Y, Tomlinson BK, et al. Safety and Efficacy of Decitabine plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings. Presented at: 62nd American Society of Hematology Annual Meeting & Exposition, December 5-8, 2020. Abstract 170.

Related Items
Tibsovo Received a New Indication, in Combination with Azacitidine, for Newly Diagnosed Patients with AML and IDH1 Mutation
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Leukemia
Vidaza Received New Indication for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Leukemia, Pediatric Cancer
Arsenic Trioxide–Induced QTc Interval Prolongation and the Potential Benefit of Beta-Blockers in Patients with Acute Promyelocytic Leukemia: Case Series
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in Case Reports, Leukemia, Adverse Events
Effect of Concomitant Azole Antifungals on Duration of Myelosuppression in Newly Diagnosed Patients with AML Receiving Venetoclax in Combination with Cladribine and Low-Dose Cytarabine
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Leukemia
Dasatinib-Induced Gynecomastia in 2 Patients with Chronic Myeloid Leukemia: Case Reports and Review of the Literature
Jessie Signorelli, PharmD, BCOP, Amir T. Fathi, MD, Gabriela Hobbs, MD
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in Case Reports, Leukemia, Adverse Events
Lidocaine plus Tetracaine–Medicated Patch Used for Propofol Sedation During Lumbar Punctures in Pediatric Patients with Blood Cancer
Lisa R. Garavaglia, PharmD , Frank Casey, MD, Lesley Cottrell, PhD, Claudiu Faraon-Pogaceanu, MD, Stephan Paul, MD, Melvin Lee Wright, DO
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in Original Article, Pediatric Cancer, Leukemia, Lymphoma
Myeloablative and Reduced-Intensity Preparative Regimens for Allogeneic Transplant in the Outpatient versus Inpatient Setting in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
Gretchen Pardo, PharmD, Beth Eddy, PharmD, BCOP, Zahra Mahmoudjafari, PharmD, BCOP, Dennis Grauer, PhD, MS, Joseph McGuirk, DO
JHOP - August 2021 Vol 11, No 4 published on August 17, 2021 in Original Article, Transplant, Leukemia, Myelodysplastic Syndromes, Conditioning Regimen
Pharmacy Resident–Led Medication Reconciliation and Patient Education Service in Adults with Leukemia Receiving Anticancer Oral Agents: A Pilot Study
Lily Y. Jia, PharmD, BCOP, Jessie Signorelli, PharmD, BCOP, Samantha O. Luk, PharmD, BCOP, E. Bridget Kim, PharmD, BCPS, BCOP, Gayle C. Blouin, PharmD, BCOP
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in Original Article, Leukemia, Oncology Pharmacy Programs
Pegaspargase-Induced Diabetic Ketoacidosis in a Patient with Acute Lymphoblastic Leukemia
Ellen Madarang, PharmD, BCOP, Leslie Gallardo, PharmD, BCPS, Terrence Bradley, MD
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in Case Reports, Acute Lymphoblastic Leukemia, Leukemia, Adverse Events
Oral Azacitidine Prolongs Survival in Patients with Acute Myeloid Leukemia
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in From the Literature, Leukemia
Copyright © The Lynx Group, LLC. All rights reserved.